NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-23
Reading ADPT? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround situation with a focus on achieving positive adjusted EBITDA and free cash flow. The current thesis state is mixed, as management is making progress but still faces challenges.
The market seems to have priced in a low level of fragility, indicating that expectations are somewhat justified. There is a slight expectations gap, suggesting that while the stock is seen as premium compared to peers, it is not overly optimistic.
Fundamentals are likely to improve gradually, with management focused on revenue growth and controlling expenses. However, the elevated risk level and recent mixed results may create uncertainty in the near term.
The thesis hinges on management's ability to meet their guidance for positive adjusted EBITDA and cash flow, as well as the performance of sector bellwethers like TMO, DHR, and IDXX. Any negative shifts in these companies could impact ADPT's momentum.
Overall, ADPT's trajectory appears to be on track, but it remains sensitive to both internal execution and external sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings results will show if Adaptive is on track for positive adjusted EBITDA by end of 2026.
Confirms:Q2 earnings report shows adjusted EBITDA turning positive for the first time.
Disproves:The Q2 earnings report shows adjusted EBITDA is still negative.
Why it matters: Confirming the guidance range of $260 million to $270 million signals strong growth in the MRD business.
Confirms:Management says Q2 MRD revenue will be between $260 million and $270 million.
Disproves:Management cuts Q2 MRD revenue guidance to less than $260 million.
Why it matters: The earnings report can provide insights into revenue and expenses. It affects investor sentiment.
Confirms one read:Earnings report shows revenue growth exceeding 15% year over year.
Confirms the other:Earnings report shows revenue growth below 5% year over year.
Why it matters: If the sector's revenue growth picks up, it could help Adaptive Biotechnologies. This would signal a better environment for growth.
Confirms:Sector revenue growth rises back toward 10% year over year.
Disproves:Sector revenue growth continues to decline below 5% year over year.
Why it matters: The market's reaction to the debt issuance shows investor confidence.
Confirms one read:Stock price rises following the debt issuance announcement.
Confirms the other:Stock price falls following the debt issuance announcement.
Why it matters: A key goal for management is to reach positive adjusted EBITDA by the end of 2026.
Confirms:Adjusted EBITDA loss narrows to less than -$2.5 million for Q2.
Disproves:Adjusted EBITDA loss remains worse than -$2.5 million for Q2.
Why it matters: The announced share buyback could support the stock price and reduce dilution.
Confirms:The stock price goes up after the $25 million share buyback announcement.
Disproves:Stock price declines despite the share buyback announcement.
Why it matters: Controlling operating costs is key for good financial health.
Confirms:Operating expenses for Q2 exceed the guided range of $350 million to $360 million.
Disproves:Operating expenses for Q2 stay within or below the guided range.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
